Form 4 | Impact Biomedical Director Chan Heng Fai Ambrose sold 885,276 shares on April 2, 2025

Filings Track

04-05

Chan Heng Fai Ambrose, Director and a 10% owner of Impact Biomedical Inc., sold a total of 885,276 shares of common stock between April 2 to April 4, 2025, through his controlled entities Alset International Ltd and Alset Inc. Such intensive selling may suggest an overvaluation of the company's stock, and investors should closely monitor the potential impact of this news on the stock price.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1146810103"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1146810103\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1146810103?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-05 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146810103","market":"us","top_or_hot":-1,"title":"Form 4 | Impact Biomedical Director Chan Heng Fai Ambrose sold 885,276 shares on April 2, 2025","media":"Filings Track","content":"Chan Heng Fai Ambrose, Director and a 10% owner of Impact Biomedical Inc., sold a total of 885,276 shares of common stock between April 2 to April 4, 2025, through his controlled entities Alset International Ltd and Alset Inc. Such intensive selling may suggest an overvaluation of the company's stock, and investors should closely monitor the potential impact of this news on the stock price.","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Form 4 | Impact Biomedical Director Chan Heng Fai Ambrose sold 885,276 shares on April 2, 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForm 4 | Impact Biomedical Director Chan Heng Fai Ambrose sold 885,276 shares on April 2, 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1033292654\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Filings Track </p>\n<p class=\"h-time smaller\">2025-04-05 05:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\nChan Heng Fai Ambrose, Director and a 10% owner of Impact Biomedical Inc., sold a total of 885,276 shares of common stock between April 2 to April 4, 2025, through his controlled entities Alset International Ltd and Alset Inc. Such intensive selling may suggest an overvaluation of the company's stock, and investors should closely monitor the potential impact of this news on the stock price.\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1146810103","we_media_id":"1033292654","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146810103","pubTimestamp":1743801612,"columns":[{"name":"股东增减持","id":28,"label_key":"insiderTrades"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Filings Track","introduction":"Stay Updated with Major Exchanges' Announcements","home_visible":1,"id":"1033292654","head_image":"https://static.tigerbbs.com/f241068b466f5f9316243a75366834d5"},"summary":"Chan Heng Fai Ambrose, Director and a 10% owner of Impact Biomedical Inc., sold a total of 885,276 shares of common stock between April 2 to April 4, 2025, through his controlled entities Alset International Ltd and Alset Inc. Such intensive selling may suggest an overvaluation of the company's stock, and investors should closely monitor the potential impact of this news on the stock price.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Form 4 Impact Biomedical董事陈恒辉于2025年4月2日出售885,276股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBO":1},"content_text":"Chan Heng Fai Ambrose, Director and a 10% owner of Impact Biomedical Inc., sold a total of 885,276 shares of common stock between April 2 to April 4, 2025, through his controlled entities Alset International Ltd and Alset Inc. Such intensive selling may suggest an overvaluation of the company's stock, and investors should closely monitor the potential impact of this news on the stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"insiderTrades","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}